However, it has been demonstrated that in mouse melanoma models, the variation in treatment efficiency with timing of administration aligns with increased tumour-associated macrophages and rhythmic expression of the Pdcd1 gene Pdcd1 (encoding PD-1) [20]. The gene discussed is PDCD1; the disease is melanoma.